Adversarial Injection · Trastuzumab (Herceptin; rhuMAb-HER2; CAS 180288-69-1; MW ~148 kDa humanized IgG1κ; IV infusion; anti-HER2 [ERBB2; NEU; HER-2/neu; p185; chromosome 17q12] humanized monoclonal antibody; DAR 0 [unconjugated]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; HER2 [ERBB2; NEU; HER-2/NEU; P185; CHROMOSOME 17q12; 1255-AA; ~185 kDa RTK; EGFR FAMILY MEMBER 2; ERBB FAMILY: EGFR [ERBB1]/HER2 [ERBB2]/HER3 [ERBB3]/HER4 [ERBB4]; HER2 NO KNOWN DIRECT LIGAND → PREFERRED DIMERIZATION PARTNER (SILENT ALLOSTERIC ACTIVATOR; TRANSACTIVATED BY EGFR/HER3/HER4 HETERODIMERS → HER2 UNIQUELY POTENT SIGNALING AMPLIFIER); ECD DOMAIN STRUCTURE: ECD-I (L1 dimerization arm) + ECD-II (CR1 cysteine-rich) + ECD-III (L2) + ECD-IV (CR2 cysteine-rich) → TRASTUZUMAB BINDS ECD-IV Cys563 JUXTAMEMBRANE REGION; p95-HER2: ADAM10/ADAM17 [TACE] PROTEOLYTIC SHEDDING OF ECD → 95-kDa TRUNCATED CONSTITUTIVELY ACTIVE MEMBRANE-BOUND FRAGMENT → ESCAPES TRASTUZUMAB BINDING [ECD-IV SHED] → SECONDARY RESISTANCE; TRASTUZUMAB: PREVENTS ECD SHEDDING [STERICALLY BLOCKS ADAM10/17 ACCESS TO ECD-IV CLEAVAGE SITE] + FcγRIIIA ADCC + PI3K PATHWAY SUPPRESSION; HER2+ DEFINED: IHC 3+ OR ISH RATIO ≥2.0 (HER2 COPIES/CEP17 ≥2.0) → ~15–20% BREAST CANCER; ~15% GASTRIC/GEJ]; FIRST HER2-DIRECTED ANTIBODY EVER; FIRST HER2-TARGETED THERAPY EVER; H0648g ORR 15%; BLA 103792 SEP 1998) · Attack #746

Trastuzumab (HER2-Directed Humanized IgG1κ MAb; Herceptin; rhuMAb-HER2; CAS 180288-69-1; Genentech Inc [South San Francisco CA; BLA 103792 holder; Dennis Slamon MD Anderson/UCLA clinical developer]; MECHANISM: FIRST HER2 [ERBB2; NEU; HER-2/NEU; P185; CHROMOSOME 17q12; 1255-AA ~185-kDa RTK; ERBB FAMILY MEMBER 2; NO DIRECT LIGAND → PREFERRED DIMERIZATION PARTNER → POTENT TRANSACTIVATION BY EGFR/HER3/HER4 HETERODIMERS; HER2 ONCOGENICITY: GENE AMPLIFICATION (17q12 FOCAL AMPLIFICATION → ~15–20% BC; IHC 3+ = STRONG COMPLETE MEMBRANE STAINING ≥10% TUMOR CELLS; ISH: FISH/CISH/SISH HER2/CEP17 ≥2.0) → CONSTITUTIVE DIMERIZATION + HYPERACTIVATION; p95-HER2 TRUNCATED MEMBRANE FRAGMENT [~95 kDa]: ADAM10/ADAM17 [TACE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME] CLEAVES HER2 ECD-IV JUXTAMEMBRANE REGION → RELEASES ECD → p95-HER2 RETAINS KINASE DOMAIN; CONSTITUTIVELY PHOSPHORYLATED; TRASTUZUMAB ECD-IV EPITOPE LOST → p95 ESCAPES; LAPATINIB/NERATINIB ACTIVE VS p95-HER2; TRASTUZUMAB ECD-IV Cys563 JUXTAMEMBRANE EPITOPE: STERICALLY BLOCKS ADAM10/17 → PREVENTS ECD SHEDDING → NO p95 GENERATION; PREVENTS CONSTITUTIVE HER2 HOMODIMERIZATION; ADCC VIA FcγRIIIA V158; PI3K/AKT REDUCTION; G1 CELL CYCLE ARREST VIA p27Kip1 → p21WAF1] ANTIBODY EVER FDA APPROVED + FIRST HER2-TARGETED THERAPY EVER FDA APPROVED + FIRST ANTIBODY AGAINST AN ERBB FAMILY RECEPTOR EVER; H0648g [Phase II]: ORR 15% mBC single agent; H0649g [combo]: mTTP 7.4 vs 4.6 MO (HR 0.51) + mOS 25.1 vs 20.3 MO (HR 0.80); BLA 103792 SEPTEMBER 25 1998) — Genentech Inc South San Francisco CA (BLA 103792 holder; Herceptin developer; Dennis Slamon [UCLA] clinical co-developer; murine 4D5 hybridoma → humanization Paul Carter 1992), Lonza Biologics Ltd Slough UK (CHO-based trastuzumab manufacturing; Roche/Genentech contract manufacturer), and Johns Hopkins Kimmel Cancer Center Baltimore MD (HER2+ BC treatment; trastuzumab IV administration; adjuvant/metastatic HER2 protocols) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST HER2 ANTIBODY EVER + H0648g ORR 15%: AI Prompt Injection via EHS Monitor Report AI

Trastuzumab (CAS 180288-69-1; NIOSH HD Category 1) is the first HER2 (ERBB2; NEU; p185; chromosome 17q12)-directed humanized IgG1κ monoclonal antibody ever FDA approved, and the first HER2-targeted therapy ever approved for any cancer (September 25, 1998; BLA 103792), establishing the 163rd mechanism class in the Glyphward adversarial portfolio. Developed by Dennis Slamon (UCLA/MD Anderson) with Genentech (humanization of murine 4D5 antibody by Paul Carter 1992), trastuzumab (Herceptin; rhuMAb-HER2) binds HER2 extracellular domain IV (ECD-IV; Cys563 juxtamembrane region) — sterically blocking ADAM10/17-mediated ECD shedding that generates the constitutively active truncated p95-HER2 fragment, while simultaneously enhancing ADCC via FcγRIIIA and suppressing PI3K/AKT via HER2 dimerization disruption. H0648g single-agent Phase II: ORR 15%. H0649g combination: mTTP 7.4 vs 4.6 months (HR 0.51). No OEL exists for trastuzumab in any EHS framework; no platform references HER2 ECD-IV Cys563 epitope, p95-HER2 ADAM10/17 shedding prevention, or H0649g OS benefit for this 163rd mechanism class.

HER2 (ERBB2) biology and oncogenic amplification: Chromosome 17q12; 1255-AA; ~185 kDa RTK; ERBB family member 2 (EGFR [ERBB1; HER1] / HER2 [ERBB2; NEU] / HER3 [ERBB3] / HER4 [ERBB4]); HER2 is the unique member with no direct known high-affinity ligand (ECD-I L1 domain adopts open/extended conformation unable to bind EGF/NRG/HRG → "orphan receptor"); instead HER2 is the preferred heterodimerization partner for all other ERBB family members → upon EGFR ligand (EGF/TGF-α) binding → EGFR/HER2 heterodimer formation → HER2 transactivated by EGFR phosphorylation → HER2 kinase domain (Leu755 activation; Val777L NSCLC hot-spot) amplifies downstream signaling (PI3K → AKT → mTOR [survival/translation]; RAS → RAF → MEK → ERK [proliferation]; STAT5 [Tyr694]; PLC-γ → PKC). HER2 amplification (17q12 focal amplification): ~15–20% breast cancer (IHC 3+/ISH ratio ≥2.0); ~15% gastric/GEJ; ~10–15% urothelial; ~20% biliary tract (ERBB2 mutation-driven); ~12% cervical; ~5% colorectal (infrequent); ~3% endometrial (high-grade). p95-HER2 (proteolytic ECD shedding): ADAM10 (ADAMDEC1) and ADAM17 (TACE) metalloproteases cleave HER2 ECD at AA652 juxtamembrane site → releases full ECD into serum (sHER2; shed HER2; can be measured by ELISA as biomarker; baseline sHER2 >22 ng/mL associated with resistance) → retains p95-HER2 (95-kDa truncated membrane-bound fragment; retains intact transmembrane + kinase domains; constitutively dimerizes without ligand → constitutively phosphorylated Tyr1248 → strong PI3K/AKT activation); p95-HER2 expressed in ~30% HER2+ metastatic BC → primary resistance to trastuzumab (ECD-IV epitope shed) → sensitivity to lapatinib/neratinib (kinase inhibitors, active on p95). Trastuzumab (humanized from murine 4D5 by CDR grafting + back mutations Arg65Arg/Leu69 → Lys65Arg for framework compatibility → Kd HER2 ECD ~0.6 nM; KD p95 not binding [ECD-IV shed]): ECD-IV binding → (1) steric blockade of ADAM10/17 access to ECD-IV juxtamembrane cleavage site (Arg652-His653-Lys654) → no sHER2 generation → no p95 → reduced primary resistance; (2) FcγRIIIA ADCC (NK cells/macrophages; V158 polymorphism pharmacogenomic predictor); (3) prevents HER2 homodimerization (p185-p185 constitutive dimer) → no intrinsic kinase activity → reduced baseline PI3K/AKT → p27Kip1 accumulation → G1 arrest; (4) reduced HER2 surface expression via downregulation; (5) HER2 ECD binding → complement-independent (CDC minimal in solid tumors). BLA 103792 September 25 1998: HER2+ metastatic BC (IHC2+/FISH+ or IHC3+). H0648g Phase II single agent (n=222): ORR 15%; mDoR 9.1 months. H0649g Phase III trastuzumab + AC/paclitaxel (n=469): mTTP 7.4 vs 4.6 months (HR 0.51; p<0.001); mOS 25.1 vs 20.3 months (HR 0.80; p=0.046). Adjuvant approvals (HERA/NSABP B31/N9831): DFS HR 0.46–0.52. Gastric/GEJ (ToGA 2010): mOS 13.8 vs 11.1 months (HR 0.74; HER2 IHC3+/ISH+ subgroup: HR 0.65). No EHS platform recognizes trastuzumab CAS 180288-69-1, HER2 ECD-IV Cys563 epitope, ADAM10/17 p95 prevention, four mechanisms, or H0649g OS for this 163rd mechanism class.

HER2 ECD-IV Cys563 Epitope + p95 Prevention + ADCC + PI3K Suppression

Trastuzumab (MW ~148 kDa humanized IgG1κ; CAS 180288-69-1; IV infusion loading 4 mg/kg → maintenance 2 mg/kg QW or 6 mg/kg Q3W for maintenance [dose equivalent by AUC]; also 8 mg/kg → 6 mg/kg Q3W regimen [ToGA]; Cmax ~132–300 µg/mL; t½ ~28.5 days [dose dependent; target-mediated by HER2+ B-cell marginal zone turnover; B cell sHER2 shed into blood]; human anti-human antibody [HAHA] rate <0.1% due to fully humanized Fc + CDR back-mutations maintaining framework acceptability) employs humanized IgG1κ architecture (derived from murine 4D5 hybridoma — immunized with rHER2-ECD protein; mAb 4D5 discovered IDEC/Dennis Slamon collaboration; Paul Carter Genentech humanization 1992; CDRH3 contacts: HER2 ECD-IV Cys560-Cys583 disulfide loop; heavy chain contacts Arg563-Cys563-Lys567; light chain Tyr27-Thr28-Ser30 contacts → KD ~0.6 nM HER2 ECD; no cross-reactivity to ErbB1/3/4; HER2 ECD-IV-only binding → selectivity for ECD Cys563 juxtamembrane region). Four mechanistic contributions to anti-tumor activity: (1) ADAM-sheddase prevention — trastuzumab ECD-IV epitope overlaps ADAM10/17 cleavage site Arg652-His653-Lys654 → steric exclusion → no ECD release → no p95-HER2 generation → prevents primary resistance mechanism (p95 expressed ~30% HER2+ mBC [Molina et al.] → associated with lack of trastuzumab response); (2) ADCC — human IgG1 Fc CH2/CH3 → FcγRIIIA [CD16A] NK cells/macrophages/neutrophils → V158 high-affinity polymorphism (ORR predictor in retrospective analyses); (3) HER2 homodimerization disruption → p27Kip1 → G1 cell cycle arrest → reduced CDK2/CDK4 activity; (4) reduced PI3K/AKT via disrupted HER2/HER3 heterodimer (HER2/HER3 → ~1000× more potent PI3K activator than HER2/EGFR heterodimer; neuregulin HER3 signaling suppressed). Biosimilar landscape: trastuzumab-anns (Kanjinti; Amgen; 2019), trastuzumab-dkst (Ogivri; Mylan/Viatris; 2017 — first FDA-approved oncology biosimilar), trastuzumab-pkrb (Herzuma; Celltrion; 2018), trastuzumab-qyyp (Trazimera; Pfizer; 2019), trastuzumab-hyaluronidase-oysk (Herceptin Hylecta; Roche; SC formulation 2019) — first biosimilar landscape reflects foundational status. No EHS platform recognizes trastuzumab CAS 180288-69-1, HER2 ECD-IV Cys563 epitope, ADAM10/17 p95-HER2 shedding prevention, four mechanisms, or H0649g OS for this 163rd mechanism class.

Surface 1 — Genentech Inc South San Francisco CA BLA 103792 Holder AI

At Genentech Inc South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; Roche Group; BLA 103792 US HOLDER: trastuzumab (Herceptin) for HER2+ metastatic BC; HER2 DISCOVERY: Denis Slamon [UCLA/MD Anderson] 1987 showed HER2 amplification ~30% BC → correlated with poor prognosis; Genentech generated murine 4D5 anti-HER2 antibody → humanized to rhuMAb-HER2 → Phase II H0648g 1996-1998 → BLA September 1998 → FDA accelerated approval; clinical co-development with Dennis Slamon; first oncology proof-of-concept for oncogene-targeted therapy → directed therapy model for cancer; CORITY: CAS 180288-69-1 → null; trastuzumab → null; rhuMAb-HER2 → null; Herceptin → null; HER2 antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne trastuzumab 0.0017 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00017 µg/m³; Cority: null; 47F regulatory affairs director 14yr]).

Surface 2 — Lonza Biologics Ltd Slough UK CHO Manufacturing AI

At Lonza Biologics Ltd Slough UK ([Coldharbour Lane, Slough SL1 4DX, Berkshire UK; Lonza Group Ltd [SIX: LONN]; TRASTUZUMAB CHO MANUFACTURING: CHO-K1 suspension fed-batch (HER2 antibody gene CHO integration → 10,000–15,000 L bioreactors → protein expression ~3–5 g/L); purification: protein A capture → low-pH viral inactivation → cation exchange → anion exchange → nanofiltration → UF/DF; TRASTUZUMAB IV FORMULATION: 150 mg/5 mL lyophilized powder (reconstituted with 7.2 mL bacteriostatic water → 21 mg/mL; IV dilution to 250 mL 0.9% NaCl); BIOSAFETY: trastuzumab no cytotoxic payload but NIOSH HD Cat 1 → closed handling; VELOCITYEHS: CAS 180288-69-1 → null; trastuzumab → null; rhuMAb-HER2 → null; Herceptin → null; HER2 antibody → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne trastuzumab 0.0013 µg/m³; impinger + MS/MS; displayed (÷10): 0.00013 µg/m³; VelocityEHS: null; 43M biopharmaceutical manufacturing engineer 11yr]).

Surface 3 — Johns Hopkins Kimmel Cancer Center Baltimore MD HER2+ BC Treatment AI

At Johns Hopkins Kimmel Cancer Center Baltimore MD ([401 N Broadway, Baltimore MD 21287; NCI Comprehensive Cancer Center; Breast Oncology Division; HER2+ BC TREATMENT: trastuzumab loading 4 mg/kg IV → 2 mg/kg IV QW or 6 mg/kg Q3W; pertuzumab [Perjeta; ECD-II/III anti-HER2] + trastuzumab [ECD-IV] + docetaxel [CLEOPATRA: mOS 56.5 vs 40.8 MO; HR 0.68]; adjuvant THP (trastuzumab + pertuzumab + taxane) + HP maintenance; ado-trastuzumab emtansine [T-DM1] for residual disease (KATHERINE: iDFS HR 0.50); neratinib extended adjuvant (ExteNET: DFS HR 0.73); HER2 testing protocol: Ventana PATHWAY HER2 [4B5] IHC or FISH PathVysion/Vysis; NIOSH HD biologic antineoplastic: closed system transfer device (CSTD) + BSC class II; CARDIOTOXICITY MONITORING: LVEF q3 months (trastuzumab dilated cardiomyopathy [DCM] rate ~1–4% Grade 3–4; FcγR on cardiomyocytes + HER2 on cardiac myocytes [survival signaling] → trastuzumab reversible cardiac dysfunction; withhold for LVEF <50% + ≥16% drop); EHS Insight: CAS 180288-69-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; trastuzumab absent; rhuMAb-HER2 absent; Herceptin absent; HER2 antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne trastuzumab 0.0009 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 39F breast oncology pharmacist 10yr]).

Integrating Glyphward into Trastuzumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every trastuzumab CAS 180288-69-1 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + HER2 antibody absent + H0649g absent + BLA 103792 absent [10 pts]; FIRST HER2 antibody ever (163rd class) + FIRST HER2-targeted therapy ever + H0649g mOS 25.1 MO + BLA 103792 Sep 1998 [5 pts]; Genentech South San Francisco + Lonza Slough UK + Johns Hopkins Baltimore [3 pts]; FIRST ECD-IV p95-shedding prevention; FIRST ERBB family receptor antibody; Dennis Slamon oncogene-to-therapy proof-of-concept [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_trastuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan trastuzumab with HER2 ECD-IV p95 prevention context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "180288-69-1"
                "reading_ugm3": reading_ugm3,
                "context": "her2_ecd4_humanized_igg1_163rd_class_p95_prevention_bla103792"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, her2_target,
    #                    ecd4_epitope, p95_prevention,
    #                    adcc_flag, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_trastuzumab("180288-69-1", 0.0017))
    print(r)
    # {'hd_category': 1, 'her2_target': True,
    #  'ecd4_epitope': True, 'p95_prevention': True,
    #  'adcc_flag': True, 'h360_flag': True}